MAPT and Alzheimer disease: We analyzed the relationship between baseline [18F]GTP1 tau PET indices and longitudinal cognitive change over 18 months across multiple assessments in a cohort of participants ranging from cognitively normal (CN) controls through AD patients with moderate dementia.